Obsessive-compulsive Disorder
📧 Sign up to get email alerts when something new happens for Obsessive-compulsive Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-09-27FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for fluoxetine from Aurobindo Pharma Limited, allowing the generic product to be marketed under the …
-
CLINICAL_TRIALS trial_result · 2012-09-18Clinical Trial Update: The Use of D-Cycloserine to Augment CBT for Pediatric OCD [Phase 2]
A Phase 2 clinical trial from UCLA is evaluating D-Cycloserine to augment cognitive behavioral therapy for pediatric obsessive-compulsive di…
-
CLINICAL_TRIALS trial_result · 2012-08-02Clinical Trial Update: Effect of Cognitive Behavioral Therapy in OCD Highlighted by Neuropsychological Tests and MRI: Pathophysiology and Treatment Outcome Predictors
A completed trial in obsessive-compulsive disorder evaluated the impact of cognitive-behavioral therapy and explored neuropsychological test…
-
FDA approval · 2012-07-31FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for fluoxetine hydrochloride from PAI Holdings (PAI Pharma), confirming approval of a generic fluoxe…
-
CLINICAL_TRIALS trial_result · 2012-07-31Clinical Trial Update: Study of Repetitive Transcranial Magnetic Stimulation Efficacy on Obsessive Compulsive Disorder (OCD) [Phase 2]
A Phase 2 trial evaluating repetitive transcranial magnetic stimulation for Obsessive-Compulsive Disorder has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2012-07-31Clinical Trial Update: Booster as an Adjunct to Internet-based Cognitive Behavior Therapy (CBT) [Phase 2]
Phase 2 trial evaluating a booster as an adjunct to internet-based CBT for obsessive-compulsive disorder has completed.
-
FDA approval · 2012-07-31FDA Approved: PAROXETINE — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for a generic paroxetine hydrochloride product submitted by NorthStar Rx LLC.
-
FDA approval · 2012-07-31FDA Approved: PAROXETINE — Supplemental Application (Zydus Lifesciences Limited)
The FDA approved a supplemental application for paroxetine hydrochloride from Zydus Lifesciences Limited, authorizing its marketing as a gen…
-
CLINICAL_TRIALS trial_result · 2012-07-06Clinical Trial Update: Effectiveness of D-Cycloserine as an Aid to Enhance Learning for Individuals With OCD Receiving Behavior Therapy [Phase 3]
Phase 3 trial evaluating D-Cycloserine as an adjunct to behavior therapy for obsessive-compulsive disorder; the study is completed and resul…
-
CLINICAL_TRIALS trial_result · 2012-05-30Clinical Trial Update: Wait-list Study of One-Week Intensive Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder (OCD) [NA]
This is an update on a completed Mayo Clinic clinical trial evaluating a one-week intensive cognitive-behavioral therapy program for pediatr…
-
CLINICAL_TRIALS trial_result · 2012-04-27Clinical Trial Update: Study of NPL-2003 in Adolescents With Obsessive Compulsive Disorder (OCD) [Phase 2]
A Phase 2 trial of NPL-2003 in adolescents with obsessive-compulsive disorder has been terminated.
-
FDA approval · 2012-04-19FDA Approved: FLUOXETINE — Supplemental Application (TIME CAP LABORATORIES, INC.)
FDA approved a supplemental application for fluoxetine hydrochloride from Time Cap Laboratories, Inc., updating the regulatory status of thi…
-
FDA approval · 2012-04-10FDA Approved: PAROXETINE HYDROCHLORIDE — Supplemental Application (Apotex Corp)
FDA approved a supplemental application for paroxetine hydrochloride submitted by Apotex Corp.
-
CLINICAL_TRIALS trial_result · 2012-04-02Clinical Trial Update: Pilot Study of Minocycline (NPL-2003) in Adults With Obsessive-Compulsive Disorder (OCD) [Phase 2]
Phase 2 pilot trial evaluating minocycline in adults with obsessive-compulsive disorder has been completed, with results posted.
-
CLINICAL_TRIALS trial_result · 2012-03-21Clinical Trial Update: Exposure and Response Prevention With Behavioral- Versus Cognitive Therapy Rationale in Obsessive Compulsive Disorder [NA]
The completed trial evaluates the rationale for using exposure and response prevention with behavioral therapy versus cognitive therapy in O…
-
CLINICAL_TRIALS trial_result · 2012-03-16Clinical Trial Update: Cognitive Behavioral Therapy Plus Motivational Interviewing for Treatment of Obsessive-Compulsive Disorder [Phase 1]
Phase 1 clinical trial evaluating Cognitive Behavioral Therapy plus Motivational Interviewing for Obsessive-Compulsive Disorder has complete…
-
CLINICAL_TRIALS trial_result · 2012-03-06Clinical Trial Update: Fluoxetine for Obsessive-Compulsive Disorder in Children and Adolescents With Bipolar Disorder [Phase 4]
A Phase 4 trial evaluating fluoxetine for pediatric bipolar disorder with comorbid pediatric obsessive-compulsive disorder was terminated, w…
-
FDA approval · 2012-02-28FDA Approved: FLUOXETINE — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approves a supplemental application for a generic fluoxetine hydrochloride product from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2012-02-28FDA Approved: FLUOXETINE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approves the supplemental application for fluoxetine from Alembic Pharmaceuticals Limited, enabling the generic fluoxetine product to be…
-
CLINICAL_TRIALS trial_result · 2012-02-28Clinical Trial Update: Efficacy Study of Transcranial Magnetic Stimulation for Treatment of Obsessive-Compulsive Disorder [Phase 2]
Phase 2 efficacy study of transcranial magnetic stimulation for obsessive-compulsive disorder has completed.
-
CLINICAL_TRIALS research · 2012-01-05Clinical Trial Update: Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome [NA]
This entry reports on a safety and feasibility evaluation of the HBDL Coil Transcranial Magnetic Stimulation device for Tourette syndrome, w…
-
FDA approval · 2011-12-27FDA Approved: PAROXETINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application from Mylan Pharmaceuticals for paroxetine hydrochloride hemihydrate, authorizing a generic version o…
-
FDA approval · 2011-12-15FDA Approved: PAROXETINE — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application for Apotex Corp. to manufacture and market paroxetine hydrochloride as a generic antidepressant.
-
FDA approval · 2011-11-22FDA Approved: FLUOXETINE — Supplemental Application (TIME CAP LABORATORIES, INC.)
FDA approved a supplemental application for fluoxetine hydrochloride from Time Cap Laboratories, Inc., enabling the generic product Fluoxeti…
-
CLINICAL_TRIALS trial_result · 2011-11-09Clinical Trial Update: Deep Brain Stimulation for Treatment-Resistant Obsessive Compulsive Disorder [NA]
This update notes the completion of a clinical trial evaluating deep brain stimulation for treatment-resistant Obsessive-Compulsive Disorder…